Table 2.
Clinical trials related to cellular components of pre-metastatic niche formation
| Cellular type | Title | Disease or conditions | Interventions | Phase | Trial number |
|---|---|---|---|---|---|
| Macrophage | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | Metastatic Adenocarcinoma of the Colon or Rectum | Imalumab | Phase 1 | NCT01765790 |
| Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC) | Colorectal Cancer Metastatic to Liver, Gastric Cancer Metastatic to Liver | CDK-004 | Phase 1 | NCT05375604 | |
| Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Melanoma | Vusolimogene, oderparepvec | Early Phase 1 | NCT06216938 | |
| Neutrophil | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | Metastatic Breast Adenocarcinoma | Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein | Phase 1 | NCT04521764 |
| Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PROSPECTA) | Prostate Cancer | G-CSF, Ciprofloxacin, CABAZITAXEL, Prednisone | Phase 4 | NCT01649635 | |
| MDSCs | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | Metastatic Melanoma | SX-682, Pembrolizumab | Phase 1 | NCT03161431 |
| Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Metastasis to Brain | Nivolumab,Ipilimumab, Relatlimab | Early Phase 1 | NCT05704933 | |
| Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Non Small Cell Lung Cancer Stage IIIB | Nivolumab, Gemcitabine | Phase 2 | NCT03302247 | |
| Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | Metastatic Malignant Solid Neoplasm | Ibrutinib | Phase 1 | NCT03525925 | |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | Metastatic Colorectal Carcinoma | CXCR1/2 Inhibitor SX-682, Nivolumab | Phase 1 | NCT04599140 | |
| T cells | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases | Metastatic Malignant Neoplasm in the Brain | Chimeric Antigen Receptor T-Cell Therapy | Phase 1 | NCT03696030 |
| Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | Metastatic Melanoma | Lymphodepletion, Vemurafenib, High Dose Interleukin-2 | Phase 2 | NCT01659151 | |
| A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | Metastatic Cancer | OMP-313M32, Nivolumab | Phase 1 | NCT03119428 | |
| A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/ Metastatic Soft Tissue and Bone Sarcoma | Soft Tissue Sarcoma | Cyclophosphamide, attIL2-T cells | Phase 1 | NCT05621668 |